Neurovalens
Non-invasive neurostimulation devices for insomnia and anxiety.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | £6.0m | Debt | |
| Total Funding | 000k | ||
Related Content
Neurovalens is a global health-tech company focused on developing non-invasive neurostimulation products to solve some of the world’s most significant health challenges. The company’s Modius technology is FDA-cleared, non-invasive, and influences the deep parts of the brain with a small and safe electrical pulse. The noninvasive approach removes the need for surgical implantation and allows much earlier intervention in the treatment pathway.
Neurovalens is currently working to release several versions of the technology to treat various disorders. Modius Sleep is the first product to be released in October of 2024. The Neurovalens headquarters is in Belfast, United Kingdom.
Product Line:
● Modius Sleep (released October 2024)
● Modius Calm (release date TBD)
● Ongoing clinical trial research is currently taking place for additional products designed to treat PTSD, diabetes, and depression.